Breaking News

Horizon Therapeutics Buys EirGen Manufacturing Facility

The 44,000 square foot facility in Ireland includes fill-finish and analytical laboratory capabilities with potential for site expansion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Horizon Therapeutics has inked a $65 million deal to purchase a drug product manufacturing facility from EirGen Pharma in Waterford, Ireland. The facility, which is located in an IDA Ireland business park, includes a filling line and lyophilizer, or freeze dryer, that can be used for both Horizon’s commercial medicines, including its rare disease biologics TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase injection) and UPLIZNA (inebilizumab-cdon), and its development compounds.   Horizon will...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters